Bristol Myers Squibb Partners with Kasey Keller to Highlight Breyanzi’s 62% Risk Reduction
Bristol Myers Squibb has launched a collaboration with former U.S. goalkeeper Kasey Keller to publicly share his treatment journey using Breyanzi CAR T cell therapy for relapsed or refractory large B-cell lymphoma. At three-year follow-up, Breyanzi reduced the risk of events by an average of 62% versus standard care.
1. Bristol Myers Squibb Enlists Kasey Keller to Raise Awareness for Breyanzi
Bristol Myers Squibb has partnered with former U.S. Men’s National Team goalkeeper Kasey Keller to share his decade-long journey battling non-Hodgkin lymphoma and the impact of Breyanzi® (lisocabtagene maraleucel) on his outcome. Keller, who cycled through multiple therapies since his 2010 diagnosis, publicly credited a one-time infusion of personalized CD19-directed CAR T cell therapy with shifting his prognosis. At a three-year follow-up, Breyanzi demonstrated a 62% average reduction in risk of disease-related events versus standard care. Through this collaboration, launched on World Cancer Day, Bristol Myers Squibb aims to address the fact that only 20% of eligible patients currently receive cell therapy, by using Keller’s story to drive patient and provider education about CAR T options.
2. Oxford Biomedica Signs Multi-Year Supply Deal for BMS CAR-T Vectors
Oxford Biomedica (OXB) has expanded its strategic partnership with Bristol Myers Squibb by signing a Commercial Supply Agreement effective 2026 for the manufacture and delivery of lentiviral vectors used in BMS’s CAR-T cell therapy programs. The initial five-year term, with extension options, covers production at OXB facilities in Oxford, UK, and Durham, NC, and is expected to contribute materially to OXB’s medium-term revenue guidance. This agreement follows an existing relationship dating to March 2020 and underscores BMS’s confidence in OXB’s capability to supply commercial-grade vectors at scale, supporting the transition of multiple CAR-T candidates from clinical development toward broad patient access.
3. Reblozyl Franchise Poised to Offset Legacy Drug Pressure in Q4 Results
As Bristol Myers Squibb approaches its fourth-quarter earnings, investors are focused on the momentum of Reblozyl (luspatercept-aamt), which has grown into a franchise exceeding $2 billion in annual sales. With key legacy immuno-oncology drugs facing biosimilar and generic competition, Reblozyl’s double-digit year-over-year revenue growth and expanding label in lower-risk myelodysplastic syndromes are expected to be central to the company’s top-line performance. Analysts note that maintaining Reblozyl growth above 20% year-over-year will be critical for offsetting mid-single-digit declines in mature oncology products and sustaining overall revenue stability.